Company Overview of Mylan Specialty L.P
Mylan Specialty L.P is engaged in the development, manufacture, and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions, and psychiatric disorders. It offers EpiPen and EpiPen Jr auto-injectors for the emergency treatment of life-threatening allergic reactions caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. The company also provides PERFOROMIST, an inhalation solution that is used for the long-term treatment of chronic obstructive pulmonary disease, including chronic inflammation of the lungs and emphysema; EMSAM, a skin patch used to treat major depressive dis...
110 Allen Road
Basking Ridge, NJ 07920
Founded in 1978
Key Executives for Mylan Specialty L.P
Chief Financial Officer and Senior Vice President
Senior Vice President of Operations
Senior Vice President of Quality Systems
Compensation as of Fiscal Year 2014.
Mylan Specialty L.P Key Developments
Mylan Specialty Gets Contract for Epinephrine Auto-Injectors
Sep 23 13
Mylan Specialty has been awarded a maximum $62,620,232 modification (P00003) exercising the first option-year period of a one-year base contract (SPM2D0-12-D-0020) with seven one- year option periods for epinephrine auto-injectors. The contract is a fixed-price with an economic-price-adjustment, indefinite-delivery/indefinite-quantity contract. Location of performance is New Jersey with a September 26, 2014, performance completion date. Using military services are Army, Navy, Air Force, Marine Corps, and federal civilian agencies. Type of appropriation is fiscal 2013 warstopper funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pa.
Mylan Specialty Appoints Roger Graham as President
Jun 24 13
Mylan Inc. announced the appointment of Roger Graham as president of Mylan Specialty. Graham will report to Tony Mauro, president of Mylan North America. Graham joins the company from Advandx. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets. Prior to that, Graham spent nearly a decade in executive-level marketing and sales positions at three brand pharmaceutical firms, Auxilium Pharmaceuticals, Adolor Corporation and Yamanouchi Pharma America, where he established, rebuilt and/or expanded U.S. commercial operations.
Mylan, Inc. Announces Court of Appeals for the Federal Circuit Has Ruled in Favor of Mylan Specialty L.P
May 21 13
Mylan Inc. announced that the Court of Appeals for the Federal Circuit has ruled in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist(R). The Court's reversal of the summary judgment decision reinstates Mylan Specialty's patents as valid and enforceable. Mylan previously announced a settlement agreement with Sunovion resolving the litigation relating to Sunovion's Brovana(R) product, pending the outcome of the Federal Circuit appeal.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|